Drugs / Thiarabine
Thiarabine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01139151 | Aug 2010 → Nov 2011 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thiarabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01139151 ↗ |
| Known as | 4'-thioaracytidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1631221 ↗ |
| Known as | OSI-7836 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1631221 ↗ |
| Known as | Thio-cytarabine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1631221 ↗ |
| Modality | Small molecule | — CHEMBL1631221 ↗ |
| Route | Intravenous | “You will receive thiarabine by vein over about 1 hour (+/- 15 minutes) on Days 1-3 (Group 1) or Days 1-5 (Group 2) of each cycle.” NCT01139151 ↗ |